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g.2013.1Abstract Background: Liver cancer is the ﬁfth most common cancer in men and the seventh in
women. Hepatocellular carcinoma (HCC) is responsible for signiﬁcant morbidity and mortality
in patients with liver cirrhosis and accounts for 90% of primary liver cancer. Synovial sarcoma
X chromosome (SSX) genes belong to cancer testis antigens (CTA) family; expressed only in germ
cell tumors. There have been some studies about the SSX genes expression in the HCC. To the best
of our knowledge no reports included these genes expression in the Egyptian patients with HCC.
Aim: This study aims to evaluate the SSX-1 and SSX-5 mRNA expression in tumor cells circu-
lating in the peripheral blood (PB) of a cohort of Egyptian patients with HCC and to ﬁnd out any
possible associations between these genes expression and different clinical/laboratory parameters.
Subjects and methods: This study included 100 subjects; 52 HCC cases, 25 with post viral hepa-
titis liver cirrhosis and 23 apparently healthy controls. Expression of SSX-1 and SSX-5 mRNA in
PB was tested by reverse transcription polymerase chain reaction (RT-PCR).itute, SSX, synovial sarcoma X chromosome, HCC, hepatocellular carcinoma, CTA, cancer testis antigen,
atocellular carcinoma, HCV, hepatitis C virus, HBV, hepatitis B virus, AFP, alpha feto-protein, RNA,
onucleic acid, RT-PCR, reverse transcription polymerase chain reaction, EDTA, ethylene-diamine-tetra-
triphosphate, DNA, deoxyribonucleic acid, cDNA, cyclic deoxyribonucleic acid, PBS, phosphate buffer
package for social science program, n, number, CTC, circulating tumor cells
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46 A. Fawzy et al.Results: SSX-1 and SSX-5 mRNA were expressed in 40.4% and 36.5% of the HCC patients,
respectively. SSX-1 and/or SSX-5 were not detected in healthy controls or cirrhotic patients. Nei-
ther SSX-1 nor SSX-5 expression showed an association with Alfa-Fetoprotein (AFP) levels, tumor
size, tumor differentiation, hepatitis B infection and Bilharziasis (P> 0.05).
Conclusion: SSX-1 and SSX-5 mRNA are speciﬁcally expressed in tumor cells circulating in PB
of HCC patients and thus could be used as easy access, simple method molecular markers for early
diagnosis of HCC patients in Egypt.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
Liver cancer is the ﬁfth most common cancer in men and
the seventh in women [1]. During the past 20 years, the inci-
dence of HCC has tripled while the 5-year survival rate re-
mained below 12%. HCC is responsible for signiﬁcant
morbidity and mortality in patients with liver cirrhosis and
accounts for 90% of primary liver cancer [1,2]. Most of
HCCs in the world occur in the setting of cirrhosis and over
half-million people develop liver cancer every year and an
almost equal number die of it [3]. HCC is one of the most
aggressive cancers. Less than 10% of the patients, who show
progression to the terminal stage, have one year survival [4].
In Egypt, liver cancer is considered a major health problem.
According to the Egyptian NCI registry, held from January
2002 to December 2003, liver cancer ranked the 2nd most
common cancer site, after bladder cancer, in males (11.3%
of the newly diagnosed cases) and ranked the 7th cancer
site, 3.7% of the newly diagnosed female cases. Ninety per-
cent of these liver cancers were diagnosed as HCC [5]. This
may be attributed to the high prevalence rate of HCV infec-
tion in Egypt [6,7]; the main etiological factor in this
population.
The SSX gene family, which was originally identiﬁed as
fusion partners to the SYT gene in synovial sarcomas, con-
sists of 9 subtype genes (SSX 1–9). The known SSX family
members share high homology at the protein and DNA level.
Also, naturally occurring serologic responses mounted by
cancer patients against one SSX family member cross-react
with other members of the family [8]. They are also capable
of eliciting spontaneously humoral and cellular immune re-
sponses in cancer patients, and are potentially useful targets
in cancer vaccine-based immunotherapy [9]. The expression
of the SSX-1 and SSX-5 genes in normal tissues is found
to be limited to testis, and they are expressed at a low level
in the tissue of thyroid, but expressed at a different frequency
in many other kinds of tumors [9,10]. Other researchers sug-
gested that there is a close relationship between the expres-
sion of the SSX-1 gene and the occurrence of metastasis,
recurrence and prognosis of tumors [11]. There have been
some reports about the expression of SSX-1 and SSX-5 genes
in HCC [9]. Mean-while, up to our knowledge, none of these
studies included any data about the Egyptian patients with
HCC. Therefore, the aim of this work was to investigate
the SSX-1 and SSX-5 mRNA expression in tumor cells circu-
lating in the peripheral blood of a cohort of Egyptian pa-
tients with HCC. Also, the study aimed to ﬁnd out any
possible associations between these genes expression and dif-
ferent clinical/laboratory parameters.2. Subjects and methods
2.1. Subjects
This study included 100 subjects collected during the time
period from October 2012 to February 2013. They were di-
vided into three groups; the ﬁrst group included 52 patients
who were recruited from the oncology outpatient clinic at
the National Cancer Institute – Cairo University. Similar to
previous studies these 52 patients were preliminary diagnosed
as HCC according to noninvasive diagnostic criteria obtained
by imaging modalities [12–14] and, whenever possible, were
conﬁrmed by the gold standard histopathological examina-
tions. Patients with any cancer other than HCC, as well as
those with septicemia, chronic inﬂammatory disorders or
chronic heart disease were excluded from this study. The sec-
ond group included 25 patients who were recruited from the
National Liver Institute – Menouﬁya University and were
suffering from post HBV and/or HCV liver cirrhosis as con-
ﬁrmed by their clinical examinations, radiological ﬁndings
and serological tests for hepatitis viral markers. The third
group included 23 apparently healthy normal subjects who
were considered as the control group. These subjects had nor-
mal liver function tests and were sero-negative for hepatitis B
and C markers. All 100 subjects included in this study were
proved to have healthy thyroid gland based on free clinical
examination and normal routine thyroid function tests. Male
patients and healthy male subjects, in addition, appeared clin-
ically to have normal testicles. This study was approved by
the local institutional review board (ethics committee) as this
work was carried out in accordance with the Code of Ethics
of the World Medical Association (Declaration of Helsinki)
for experiments involving humans. Also written informed
consents were obtained from all participating subjects before
they were enrolled into the study. The clinical data and lab-
oratory results (like serum AFP levels, tests for Bilharziasis
and PCR for viral hepatitis B and C) were all collected from
the patient’s medical ﬁles.
2.2. Methods
All patients and control groups were submitted to:-
2.2.1. Sampling and RNA extraction
Peripheral blood samples (10 mL in EDTA), were collected.
Nucleated cells were isolated by the osmotic red blood cell lysis
method and the resulting cell pellets were stored at 80 C un-
til RNA extraction. Total RNA was extracted from the
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Lane 1: DNA molecular weight 100 base pairs (Promega, USA) 
Lanes 2 & 3:  ß -actin positive (160 base pairs)  
Lane 4: SSX-1 negative 
Lane 5: SSX-1 positive (422 base pairs) 
Lane 6: Negative control for SSX-1 
Figure 1 PCR products of SSX-1 in HCC patients.
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Lane 1: DNA molecular weight 100 base pairs (Promega, USA) 
Lanes 2, 3 & 4: ß -actin positive (160 base pairs) 
Lanes 5, 6 &7: SSX-5 positive (314 base pairs)
Figure 2 PCR products of SSX-5 in HCC patients.
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using QIAamp RNA Blood Mini Kit (Qiagen, Valencia, CA,
and USA). RNA concentration was determined by measuring
the absorbance at 280 nm and stored at 80 C. RNA integ-
rity was checked by gel electrophoresis and ethidium bromide
staining.
2.2.2. Reverse transcription polymerase chain reaction (RT-
PCR)
The primer sequence of the selected genes and b-actin (Prome-
ga, USA) are illustrated in Table 1. To avoid a false positive
outcome resulting from contaminating genomic DNA, we
ampliﬁed by primers selected the different exons as described
by Lu et al. [9]. Two lg of RNA was subjected to reverse tran-
scription with random primers using the GeneAmp Gold RNA
PCR Reagent Kit (Applied Biosystems, Carlsbad, CL, USA)
according to the manufacturer’s instructions. The cDNA
integrity was checked using b-actin ampliﬁcation as a control
gene. The PCR ampliﬁcation reaction contained 10 lL of a
1:5 dilution of reverse-transcribed products, 2 lL each of
15 lmol/L speciﬁc primers (sense and antisense), 2 lL of
10 mmol/L dNTP mixture (dATP, dGTP, dCTP, dTTP),
2 lL each of 10 lmol/L b-actin, 2.5 U Taq DNA polymerase
and PCR-buffer solution. The total volume was brought to
50 lL using distilled water. For conﬁrmation, the PCR ampli-
ﬁcations were performed in duplicates for each sample; using a
thermocycler (T-personal Biometra) and under the following
conditions: For SSX-1: denaturation (94 C for 45 s), anneal-
ing (54 C for 45 s) and extension (72 C for 60 s). For SSX-
5: denaturation (94 C for 45 s), annealing (52 C for 45 s),
and extension (72 C for 45 s). Products were subjected to 35
cycles of ampliﬁcation, followed by a ﬁnal extension of
15 min at 72 C. The PCR products were resolved on Ethidium
bromide-stained 2.0% Agarose gel and photographed under
ultra-violate light illumination, (Figs. 1 and 2). The length of
the PCR products of SSX-1 and SSX-5 were 422 and 314 base
pairs (bps), respectively.
2.3. Statistical analysis
Data have been collected and entered into the computer using
SPSS (Statistical Package for Social Science) program for sta-
tistical analysis (version 17; Inc., Chicago. IL). Chi-square test
has been used to measure the association between qualitative
variables. Fisher exact test has been used for 2 · 2 qualitative
variables when more than 25% of the cells had an expected
count less than 5. P-value was considered statistically signiﬁ-
cant when it is less than 0.05.Table 1 Primer sequence and product size for PCR ampliﬁcation.
Gene Primer sequence
SSX-1 Sense 50-CTAAAGCATCAG
Antisense 50-AGATCTCTTATT
SSX-5 Sense 50-GTT CTC AAA T
Antisense 50-CTC TGC TGG C
b-Actin Sense 50-CTT TGA TTG CA
Antisense 50-GAA AGC AAT G
The source of primer sequence of the selected genes and b-actin is Prom3. Results
This study included three groups. The ﬁrst group included 52
patients with HCC. They were 39 males and 13 females and
their ages ranged from 35 to 90 years with a median of
59.5 years. The second group included 25 patients with liver
cirrhosis. They were 20 males and 5 females and their ages ran-
ged from 34 to 68 years with a mean of 54.7 ± 7.1 years. The
third group included 23 healthy control subjects; 15 were males
and 8 were females. Their ages ranged from 28 to 53 years with
a mean of 51.65 ± 5.2 years. The characteristics of the HCC
patient’s group are demonstrated in Table 2.Product size (base pair)
AGAAGAGAAGC-30 422
AATCTTCTCAGAAA-30
AC CAC AGA AGA TG-30 314
TT CTC GGG CG-30
C ATT GTT GT-30 160
CT ATC ACC TC-30
ega, USA.
Table 2 Description of characteristics of Hepatocellular
carcinoma patients.
Studied variables Total number = 52 Percent
Age (years)
Median 59.5
Range 35–90
Gender
Male 39 75.0
Female 13 25.0
Tumor size:
65 cm 21 40.4
>5 cm 31 59.6
Stage
II 14 26.9
III 32 61.6
IV 6 11.5
Tumor diﬀerentiation
Well diﬀerentiated 10 19.2
Moderately diﬀerentiated 34 65.4
Poorly diﬀerentiated 8 15.4
Hepatitis B
Positive 5 9.6
Negative 47 90.4
Hepatitis C
Positive 11 21.2
Negative 41 78.8
SSX-1*
Positive 21 40.4
Negative 31 59.6
SSX-5*
Positive 19 36.5
Negative 33 63.5
Bilharziasis
Positive 11 21.2
Negative 41 78.8
AFP
Mean ± SD 5557.8 ± 30520.0
Range 2.6–218000.0
* SSX= Synovial sarcoma X chromosome gene.
48 A. Fawzy et al.4.1. Expression of both SSX-1 and SSX-5 in peripheral blood
In our study neither SSX-1 nor SSX-5 mRNA could be de-
tected in the peripheral blood of the 25 patients with liver cir-
rhosis or the 23 normal control subjects.
In the peripheral blood samples of the 52 HCC patients, 34/
52 cases (65.4%) showed positive expressions of SSX-1and/or
SSX-5 (Table 3), positive rates were (40.4%) and (36.5%) for
SSX-1 and SSX-5 expression, Figs. 1 and 2, respectively.
SSX-1 and SSX-5 were co-expressed in 6 (11.54%) out of 52
cases of HCC (Table 3).
4.2. Peripheral blood expression of SSX-1 and SSX-5 in relation
to clinical/laboratory parameters
In this study, no signiﬁcant associations were found between
SSX-1 and SXX-5 expression in peripheral blood, on one side,
and most of the clinical/laboratory parameters studied, on theother side. These parameters include age, gender, tumor stag-
ing, tumor size, degree of tumor differentiation, different AFP
serum levels, hepatitis B viral infection and Bilharziasis
(P-values were >0.05), (Table 4).
Also, our results revealed that 9/14 stage II HCC cases
(64.3%) were positive for at least one of the SSX genes expres-
sion (2 positive for SSX-1, 6 for SSX-5 and 1 for both), mean-
while, 20/32 stage III HCC cases (62.5%) were positive for at
least one of the SSX genes expression (11 positive for SSX-1, 6
for SSX-5 and 3 for both) and 5/6 stage IV HCC cases (83.3%)
were positive for at least one of the SSX genes expression (2
positive for SSX-1, 1 for SSX-5 and 2 for both).
Among the twenty-one HCC patients who had SSX-1 gene
transcripts and the nineteen HCC patients who had SSX-5
gene transcripts detected in their peripheral blood, only 6 pa-
tients 28.6% and 31.6%, respectively, showed AFP levels
>400 ng/Ml, in their serum (Table 4); consistent with the gen-
eral standard levels of AFP required for diagnosis of HCC
[15].
In the present study, 27/52 of our HCC cases (51.9%) had
prior liver cirrhosis; among which 11 were positive for HCV, 5
were positive for HBV and 11 were positive for Bilharziasis.
From the 11 positive HCV, 7 cases (63.6%) showed positive
expression of one/or both SSX genes, while, all the 5 positive
HBV cases (100%) showed positive expression of one/or both
SSX genes. Also, out of the 11 cases with post Bilharzial cir-
rhosis 7 cases (63.6%) showed positivity of one/or both SSX
genes.
Table 4 shows a signiﬁcant association between SSX-1
mRNA expression, in peripheral blood of HCC cases, and
hepatitis C infection (P-value = 0.02), while, it shows no asso-
ciation between SSX-5 mRNA expression and hepatitis C
infection (P-value = 0.16).5. Discussion
Hepatocellular carcinoma (HCC) is one of the most common
malignant tumors. It occurs mainly in patients with chronic li-
ver disease such as hepatitis B and C infection. These high-risk
patients are closely followed up, and increasing numbers of
small equivocal lesions are detected by imaging diagnosis.
They are now widely recognized as a precursor or early stage
of HCC and are classiﬁed as dysplastic nodules or early
HCC. It is considered that early HCC is a key step in the pro-
cess of HCC development and progression. However, the
molecular mechanisms of early hepato-carcinogenesis are far
from clear. Recent progress in comprehensive analysis of gene
expression is shedding some light on this issue [16]. The carci-
nogenesis of HCC is a multifactorial, multistep and complex
process. Its prognosis is poor and early diagnosis and monitor-
ing metastasis of HCC are of the utmost importance. Circulat-
ing diagnostic and prognostic molecular markers could be used
in proper postoperative treatment of patients at an early stage
of HCC development [17].
Cancer testis antigens represent a category of tumor-associ-
ated antigens normally expressed in male germ cells but not in
adult somatic tissues [18]. A number of cancer testis antigens
have been found expressed with high percentage and speciﬁcity
in HCC. The expression of SSX mRNA was investigated by
Wu et al., in HCC tissues and corresponding peripheral blood
of 37 patients with HCC, 15 samples of cirrhotic tissues and 15
Table 3 Association between the expressions of SSX-1 and SSX-5 among the studied group of Hepatocellular carcinoma patients.
Variable SSX-5 negative patients (n= 33) SSX-5 positive patients (n= 19) P-value
No. % No. %
SSX-1 negative patients (n= 31) 18 54.5 13 68.4 0.33
SSX-1 positive patients (n= 21) 15 45.5 6 31.6
SSX= synovial sarcoma X chromosome gene, n= number.
Table 4 Associations of expression of SSX-1 gene and SSX-5 gene in peripheral blood of hepatocellular carcinoma patients and
studied variables.
Studied variables SSX-1 gene expression SSX-5 gene expression
Negative patients
(n= 31)
Positive patients
(n= 21)
P-value Negative patients
(n= 33)
Positive patients
(n= 19)
P-value
No % No % No % No %
Age
<40 2 6.5 2 9.5 0.68 1 3.0 3 15.8 0.13
P40 29 93.5 19 90.5 32 97.0 16 84.2
Gender
Male 22 71.0 6 28.6 0.42 25 75.8 14 73.7 0.87
Female 9 29.0 15 71.4 8 24.2 5 26.3
Tumor size
65 cm 15 48.4 6 28.6 0.15 13 39.4 8 42.1 0.85
>5 cm 16 51.6 15 71.4 20 60.6 11 57.9
Stage
II 11 35.5 3 14.3 0.138 7 21.2 7 36.8 0.281
III 18 58.1 14 66.7 23 69.7 9 47.4
IV 2 6.4 4 19.0 3 9.1 3 15.8
Tumor diﬀerentiation
Well diﬀerentiated 7 22.6 3 14.3 0.34 6 18.2 4 21.1 0.96
Moderately diﬀerentiated 21 67.7 13 61.9 22 66.7 12 63.2
Poorly diﬀerentiated 3 9.7 5 23.8 5 15.2 3 15.8
AFP
620 9 29 3 14.3 0.45 9 27.3 3 15.8 0.62
>20 6 400 14 45.2 12 57.1 16 48.5 10 52.6
>400 8 25.8 6 28.6 8 24.2 6 31.6
Hepatitis B
Negative 30 96.8 17 81.0 0.14 31 93.9 16 84.2 0.34
Positive 1 3.2 4 19.0 2 6.1 3 15.8
Hepatitis C
Negative 21 67.7 20 95.2 0.02* 28 84.8 13 68.4 0.16
Positive 10 32.3 1 4.8 5 15.2 6 31.6
Bilharziasis
Negative 24 77.4 17 81.0 0.76 25 75.8 16 84.2 0.73
positive 7 22.6 4 19.0 8 24.2 3 15.8
SSX= synovial sarcoma X chromosome gene, n= number.
* Signiﬁcant association.
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gens (SSX-2 and SSX-5) showed in this study high speciﬁc
and high frequent expression only in HCC tissues. In corre-
sponding peripheral blood of HCC patients, the positive
expression rate of these two cancer testis antigens mRNA
was not very high [19]. However, a later study on another
two cancer testis antigens (SSX-1 and NY-ESO1) in the same
group of patients and with the same methods showed thatSSX-1 can be potentially used as a molecular marker in periph-
eral blood, with short-term recurrence rate at 46% in patients
whose peripheral blood expressed SSX-1 mRNA, while the
recurrence rate in patients with negative SSX-1 mRNA was
28.6% [9].
In a different study, speciﬁc expression of cancer testis anti-
gens was observed in AFP negative HCC, suggesting the appli-
cation of their mRNA as tumor markers to detect circulating
50 A. Fawzy et al.HCC cells [20]. Also FATE/BJ-HCC-2 (another cancer testis
antigen) mRNA expression was detected in the peripheral
blood mononuclear cells (PBMCs) of 46.67% patients, whose
HCC tissue samples were positive for FATE/BJ-HCC-2
mRNA, which implicated tumor cell dissemination in blood
circulation and related to the metastasis of HCC [21]. These
studies suggest that cancer testis antigen expressions can be
used in peripheral blood to detect HCC circulating cells.
In our study, the expression of SSX-1 and SSX-5 genes in
the peripheral blood, among a cohort of Egyptian HCC pa-
tients, was detected by RT-PCR and up to our Knowledge this
is the ﬁrst study in Egypt investigating the expression of both
genes in the peripheral blood samples rather than the tumor
tissues. Our study showed positive rates of expression of
SSX-1 and SSX-5 mRNA in the peripheral blood of HCC pa-
tients, while, their expression was not detected in the periphe-
ral blood of the cirrhotic patients’ group or the healthy
controls; therefore, indicating a considerable degree of their
speciﬁcity for HCC tumor and may suggest the importance
of detecting HCC circulating tumor cells (CTC) as recently
highlighted by some other authors [18,22]. Detecting these
transcripts in PB of early HCC patients can demonstrate
hematogeneous dissemination of tumor cells more speciﬁcally
than conventional methods, thus playing a supplementary role
in the diagnosis of HCC [23].
Chinese studies with SSX-1 expression in the peripheral
blood of HCC patients showed positive expression rates of
34.4% [24] and 38.9% [9]. These rates might be considered
fairly close to ours (40.4%) because of the difference between
the Chinese and Egyptian populations as well as that between
their sample sizes and ours. Also, they revealed that no SXX-1
expression was detected in cirrhotic liver tissues, normal liver
tissues or the peripheral blood of control patients [9].
As for the SXX-5 expression, our rate (36.5) was consider-
ably higher than that (23.1%) revealed by others [25]; who also
found that SXX-5 was not detected either in patients with he-
patic cirrhosis or in normal controls.
This study revealed no signiﬁcant associations between
mRNA expression of SSX-1 and SSX-5 and many clinical/lab-
oratory parameters in HCC patients; including age, gender, tu-
mor staging, tumor size, extent of differentiation, serum a-
fetoprotein (AFP) level and infection with hepatitis B virus
(all P-values were >0.05). Therefore, our results were conﬁrm-
ing some of the previously published studies [9,24,25].
In this study, the statistically signiﬁcant association
encountered between SSX-1 gene expression and hepatitis C
infection was indirect or negative; suggesting a possibility of
speciﬁc inhibitory effect of the HCV on the SSX-1 gene expres-
sion among the HCC cases. This effect might be related to cer-
tain characteristics speciﬁc for the HCV species prevalent in
Egypt; however we could not explain this possibility in this
study. Therefore, extensive future studies are highly recom-
mended to verify, explain or prove this suggestion.
In our study 51.9% of the HCC cases had prior liver cirrho-
sis and positivity of one/or both SSX genes was detected in
63.6% of the hepatitis C positive cases, 100% of the hepatitis
B positive cases and 63.6% of cases with post Bilharzial cirrho-
sis. These results may indicate that this group of molecular
markers seems promising as early detectors of HCC conver-
sion in cirrhotic patients but further studies have to be done.
Our results revealed no signiﬁcant association between the
SSX genes expression in the peripheral blood and the HCCtumor stages, yet, 64.3%, 62.5% and 83.3% of cases with
stages II–IV, respectively, were positive for at least one of
the SSX genes expression. The latter two rates of SSX genes
expression might have been expected to be high among the late
(more advanced) stages (III and IV), but, the former high rate
of positive expression among the early stage (II) was striking,
indicating that CTC probably appear early in circulation and it
is safe to assume that they can be detected as early as stage I.
However none of our cases was stage I so further study of this
stage is required. Also, it deﬁnitely suggests that SSX-1 and/or
SSX-5 expressions in the peripheral blood of HCC patients
have the potential to be used as early indicators for the tumor
development. Furthermore, up to 83.3% of stage IV cases were
positive for one or both genes conﬁrming its reliability in
detection of CTCs. In our study, Lack of statistical signiﬁcance
in relation between peripheral blood SSX genes expression and
HCC stages can be attributed to the small number of patients
in each stage.
The SSX proteins are a highly homologous group of CT-X
antigens with demonstrated immunogenicity in patients with
cancer, and a number of characteristics that make them attrac-
tive targets for tumor therapy. SSX2 in particular may be a
high priority target for cancer therapy based upon certain pre-
deﬁned criteria for prioritization of tumor antigens, such as tu-
mor speciﬁcity, oncogenicity, expression level, and number of
identiﬁed epitopes [26,27].
6. Conclusion
ZThe SSX-1 and SSX-5 mRNA are speciﬁcally expressed in
tumor cells circulating in the peripheral blood of patients
with HCC and could be used as easy access, simple method
molecular markers for early diagnosis of HCC patients in
Egypt.
Application of SSX genes as targets for speciﬁc immuno-
therapy could be a highly interesting point in future studies
on HCC patients in Egypt.
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